NCT03206970 2024-10-26Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)BeiGenePhase 2 Completed86 enrolled 16 charts 1 FDA